Clinical Trial Update: A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 study of rilotumumab with cisplatin and capecitabine for first-line gastric cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Rilotumumab (rilotumumab)

Snippet

Sponsor: Amgen | Conditions: Gastric Cancer | Phase 3 | Status: TERMINATED